Responsiveness and minimally important difference of SF-6D and EQ-5D utility scores for the treatment of pelvic organ prolapse

被引:21
|
作者
Harvie, Heidi S. [1 ]
Honeycutt, Amanda A. [2 ]
Neuwahl, Simon J. [2 ]
Barber, Matthew D. [3 ]
Richter, Holly E. [4 ]
Visco, Anthony G. [5 ]
Sung, Vivian W. [6 ]
Shepherd, Jonathan P. [7 ]
Rogers, Rebecca G. [8 ,9 ]
Jakus-Waldman, Sharon [10 ]
Mazloomdoost, Donna [11 ]
机构
[1] Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[2] RTI, Clin Res Network Coordinat, Res Triangle Pk, NC USA
[3] Cleveland, Dept Obstet & Gynecol, Cleveland, OH USA
[4] Univ Alabama Birmingham, Dept Obstet & Gynecol, Birmingham, AL 35294 USA
[5] Duke Univ, Dept Obstet & Gynecol, Durham, NC USA
[6] Brown, Dept Obstet & Gynecol, Providence, RI USA
[7] Univ Pittsburgh, Dept Obstet & Gynecol, Pittsburgh, PA USA
[8] Univ New Mexico, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA
[9] Univ Texas Austin, Dell Med Sch, Dept Womens Hlth, Austin, TX 78712 USA
[10] Kaiser Downey, Dept Obstet & Gynecol, Downey, CA USA
[11] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
EuroQol; health-related quality of life; minimal important difference; pelvic floor disorders; pelvic organ prolapse; Short Form 6D; utility score; QUALITY-OF-LIFE; VAGINAL PROLAPSE; HEALTH; TERMINOLOGY; STATE;
D O I
10.1016/j.ajog.2018.11.1094
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Utility preference scores are standardized, generic, health-related quality of life (HRQOL) measures that quantify disease severity and burden and summarize morbidity on a scale from 0 (death) to 1 (optimal health). Utility scores are widely used to measure HRQOL and in cost-effectiveness research. OBJECTIVE: To determine the responsiveness, validity properties, and minimal important difference (MID) of utility scores, as measured by the Short Form 6D (SF-6D) and EuroQol (EQ-5D), in women undergoing surgery for pelvic organ prolapse (POP). MATERIALS AND METHODS: This study combined data from 4 large, U.S., multicenter surgical trials enrolling 1321 women with pelvic organ prolapse. We collected condition-specific quality of life data using the Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ). A subset of women completed the SF6D; women in 2 trials also completed the EQ5D. Mean utility scores were compared from baseline to 12 months after surgery. Responsiveness was assessed using effect size (ES) and standardized response mean (SRM). Validity properties were assessed by (1) comparing changes in utility scores at 12 months between surgical successes and failures as defined in each study, and (2) correlating changes in utility scores with changes in the PFDI and PFIQ. MID was estimated using both anchor-based (SF-36 general health global rating scale "somewhat better" vs "no change") and distribution-based methods. RESULTS: The mean SF-6D score improved 0.050, from 0.705 +/- 0.126 at baseline to 0.761 +/- 0.131 at 12 months (P < .01). The mean EQ-5D score improved 0.060, from 0.810 +/- 0.15 at baseline to 0.868 +/- 0.15 at 12 months (P<.01). The ES (0.13-0.61) and SRM(0.13-0.57) were in the small-to-moderate range, demonstrating the responsiveness of the SF-6D and EQ-5D similar to other conditions. SF-6D and EQ-5D scores improved more for prolapse reconstructive surgical successes than for failures. The SF-6D and EQ-5D scores correlated with each other (r = 0.41; n = 645) and with condition-specific instruments. Correlations with the PFDI and PFIQ and their prolapse subscales were in the low to moderate range (r = 0.09-0.38), similar to other studies. Using the anchor-based method, theMID was 0.026 for SF-6D and 0.025 for EQ-5D, within the range of MIDs reported in other populations and for other conditions. These findings were supported by distribution-based estimates. CONCLUSION: The SF-6D and EQ-5D have good validity properties and are responsive, preference-based, utility and general HRQOL measures for women undergoing surgical treatment for prolapse. The MIDs for SF-6D and EQ-5D are similar and within the range found for other medical conditions.
引用
下载
收藏
页码:265.e1 / 265.e11
页数:11
相关论文
共 50 条
  • [21] Comparison of EQ-5D and SF-6D in mental health patients
    Hakkaart, L.
    Lamers, L. M.
    Bouwmans, C. A. M.
    van Straten, A.
    Donker, M. C. H.
    JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2007, 10 : S17 - S17
  • [22] COMPARING THE PERFORMANCE OF THE SF-6D AND EQ-5D ACROSS DISEASES
    Ferreira, L.
    Ferreira, P.
    Pereira, L.
    VALUE IN HEALTH, 2011, 14 (07) : A427 - A427
  • [23] EQ-5D and SF-6D performance in different patient groups
    Ferreira, Pedro L.
    Ferreira, Lara N.
    Pereira, Luis N.
    QUALITY OF LIFE RESEARCH, 2012, 21 : 7 - 7
  • [24] Comparison of EQ-5D and SF-6D utilities in Pompe disease
    T. A. Kanters
    W. K. Redekop
    M. E. Kruijshaar
    A. T. van der Ploeg
    M. P. M. H. Rutten-van Mölken
    L. Hakkaart
    Quality of Life Research, 2015, 24 : 837 - 844
  • [25] COMPARISON OF EQ-5D AND SF-6D UTILITIES IN POMPE DISEASE
    Kanters, T.
    Redekop, W.
    Hagemans, M. L. C.
    Van der Ploeg, A. T.
    Rutten-van Moelken, M. P.
    Hakkaart, L.
    VALUE IN HEALTH, 2011, 14 (07) : A418 - A418
  • [26] Systematic Review and Empirical Comparison of Contemporaneous EQ-5D and SF-6D Group Mean Scores
    Whitehurst, David G. T.
    Bryan, Stirling
    Lewis, Martyn
    MEDICAL DECISION MAKING, 2011, 31 (06) : E34 - E44
  • [27] Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Guillemin, Francis
    Flipo, Rene-Marc
    Fardellone, Patrice
    Bourgeois, Pierre
    Fautrel, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (09) : 1478 - 1483
  • [28] The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure
    Kontodimopoulos, Nick
    Argiriou, Michalis
    Theakos, Nikolaos
    Niakas, Dimitris
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (04): : 383 - 391
  • [29] Erratum to: Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
    A Simon Pickard
    Maureen P Neary
    David Cella
    Health and Quality of Life Outcomes, 8
  • [30] DESCRIBING AND COMPARING UTILITY FROM EQ-5D AND SF-6D IN A HUNTINGTON'S DISEASE POPULATION
    Clay, E.
    Perthame, E.
    Maman, K.
    Dorey, J.
    Toumi, M.
    VALUE IN HEALTH, 2011, 14 (07) : A329 - A329